Somatostatin receptor expression in thyroid disease

Helen Atkinson, James A. England, Amy Rafferty, Vim Jesudason, Karen Bedford, Laszlo Karsai, Stephen Atkin

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Somatostatin analogues are commercially available and used for the management of acromegaly and neuroendocrine tumours, but the expression of the receptors as a target in thyroid disease has not been explored. To assess somatostatin (SST) and somatostatin receptor (SSTR1-5) expression in both normal and thyroid disorders, as a potential target for somatostatin analogue therapy, 67 thyroid tissue specimens were reviewed: 12 differentiated thyroid carcinomas, 14 follicular adenomas, 17 multinodular goitres, 14 Graves disease, 10 Hashimotos thyroiditis specimens and five normal thyroids. Tissue was immunostained for SST and SSTR1-5. Positivity and the degree of positivity were recorded by double-blinded observers. Somatostatin receptor expression was highly expressed in normal tissue for SSTR1, 3, 4 and 5 (5 of 5, 4 of 5, 4 of 5 and 5 of 5 respectively) whilst SST and SSTR 2a and b were not expressed at all. The commonest receptor expressed for all pathological subtypes grouped together was SSTR2b (63 specimens). The commonest receptors expressed in differentiated thyroid cancer were SSTR5 (11 of 12 specimens) and SSTR2b (10 of 12 specimens). The commonest receptor expressed in benign disease was SSTR2b (53 of 55 specimens). SSTR5 was significantly under-expressed in Graves disease (P < 0.05). This study illustrates that SSTR 1, 3, 4 and 5 are highly expressed in normal, benign and malignant thyroid tissue. SSTR 2a and 2b appear absent in normal tissue and present in benign and malignant thyroid tissue (P < 0.02). This suggests that focussed SSTR2 treatment may be a potential therapeutic target.

Original languageEnglish
Pages (from-to)226-229
Number of pages4
JournalInternational Journal of Experimental Pathology
Volume94
Issue number3
DOIs
Publication statusPublished - Jun 2013
Externally publishedYes

Fingerprint

Somatostatin Receptors
Thyroid Diseases
Somatostatin
Thyroid Gland
Graves Disease
Thyroid Neoplasms
Hashimoto Disease
Acromegaly
Neuroendocrine Tumors
Goiter
Adenoma
somatostatin receptor type 1
Therapeutics

Keywords

  • Analogue
  • Octreotide
  • Receptor
  • Somatostatin
  • Thyroid

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology

Cite this

Atkinson, H., England, J. A., Rafferty, A., Jesudason, V., Bedford, K., Karsai, L., & Atkin, S. (2013). Somatostatin receptor expression in thyroid disease. International Journal of Experimental Pathology, 94(3), 226-229. https://doi.org/10.1111/iep.12024

Somatostatin receptor expression in thyroid disease. / Atkinson, Helen; England, James A.; Rafferty, Amy; Jesudason, Vim; Bedford, Karen; Karsai, Laszlo; Atkin, Stephen.

In: International Journal of Experimental Pathology, Vol. 94, No. 3, 06.2013, p. 226-229.

Research output: Contribution to journalArticle

Atkinson, H, England, JA, Rafferty, A, Jesudason, V, Bedford, K, Karsai, L & Atkin, S 2013, 'Somatostatin receptor expression in thyroid disease', International Journal of Experimental Pathology, vol. 94, no. 3, pp. 226-229. https://doi.org/10.1111/iep.12024
Atkinson H, England JA, Rafferty A, Jesudason V, Bedford K, Karsai L et al. Somatostatin receptor expression in thyroid disease. International Journal of Experimental Pathology. 2013 Jun;94(3):226-229. https://doi.org/10.1111/iep.12024
Atkinson, Helen ; England, James A. ; Rafferty, Amy ; Jesudason, Vim ; Bedford, Karen ; Karsai, Laszlo ; Atkin, Stephen. / Somatostatin receptor expression in thyroid disease. In: International Journal of Experimental Pathology. 2013 ; Vol. 94, No. 3. pp. 226-229.
@article{08acd78a850e40ad8f8c730928a7b839,
title = "Somatostatin receptor expression in thyroid disease",
abstract = "Somatostatin analogues are commercially available and used for the management of acromegaly and neuroendocrine tumours, but the expression of the receptors as a target in thyroid disease has not been explored. To assess somatostatin (SST) and somatostatin receptor (SSTR1-5) expression in both normal and thyroid disorders, as a potential target for somatostatin analogue therapy, 67 thyroid tissue specimens were reviewed: 12 differentiated thyroid carcinomas, 14 follicular adenomas, 17 multinodular goitres, 14 Graves disease, 10 Hashimotos thyroiditis specimens and five normal thyroids. Tissue was immunostained for SST and SSTR1-5. Positivity and the degree of positivity were recorded by double-blinded observers. Somatostatin receptor expression was highly expressed in normal tissue for SSTR1, 3, 4 and 5 (5 of 5, 4 of 5, 4 of 5 and 5 of 5 respectively) whilst SST and SSTR 2a and b were not expressed at all. The commonest receptor expressed for all pathological subtypes grouped together was SSTR2b (63 specimens). The commonest receptors expressed in differentiated thyroid cancer were SSTR5 (11 of 12 specimens) and SSTR2b (10 of 12 specimens). The commonest receptor expressed in benign disease was SSTR2b (53 of 55 specimens). SSTR5 was significantly under-expressed in Graves disease (P < 0.05). This study illustrates that SSTR 1, 3, 4 and 5 are highly expressed in normal, benign and malignant thyroid tissue. SSTR 2a and 2b appear absent in normal tissue and present in benign and malignant thyroid tissue (P < 0.02). This suggests that focussed SSTR2 treatment may be a potential therapeutic target.",
keywords = "Analogue, Octreotide, Receptor, Somatostatin, Thyroid",
author = "Helen Atkinson and England, {James A.} and Amy Rafferty and Vim Jesudason and Karen Bedford and Laszlo Karsai and Stephen Atkin",
year = "2013",
month = "6",
doi = "10.1111/iep.12024",
language = "English",
volume = "94",
pages = "226--229",
journal = "International Journal of Experimental Pathology",
issn = "0959-9673",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Somatostatin receptor expression in thyroid disease

AU - Atkinson, Helen

AU - England, James A.

AU - Rafferty, Amy

AU - Jesudason, Vim

AU - Bedford, Karen

AU - Karsai, Laszlo

AU - Atkin, Stephen

PY - 2013/6

Y1 - 2013/6

N2 - Somatostatin analogues are commercially available and used for the management of acromegaly and neuroendocrine tumours, but the expression of the receptors as a target in thyroid disease has not been explored. To assess somatostatin (SST) and somatostatin receptor (SSTR1-5) expression in both normal and thyroid disorders, as a potential target for somatostatin analogue therapy, 67 thyroid tissue specimens were reviewed: 12 differentiated thyroid carcinomas, 14 follicular adenomas, 17 multinodular goitres, 14 Graves disease, 10 Hashimotos thyroiditis specimens and five normal thyroids. Tissue was immunostained for SST and SSTR1-5. Positivity and the degree of positivity were recorded by double-blinded observers. Somatostatin receptor expression was highly expressed in normal tissue for SSTR1, 3, 4 and 5 (5 of 5, 4 of 5, 4 of 5 and 5 of 5 respectively) whilst SST and SSTR 2a and b were not expressed at all. The commonest receptor expressed for all pathological subtypes grouped together was SSTR2b (63 specimens). The commonest receptors expressed in differentiated thyroid cancer were SSTR5 (11 of 12 specimens) and SSTR2b (10 of 12 specimens). The commonest receptor expressed in benign disease was SSTR2b (53 of 55 specimens). SSTR5 was significantly under-expressed in Graves disease (P < 0.05). This study illustrates that SSTR 1, 3, 4 and 5 are highly expressed in normal, benign and malignant thyroid tissue. SSTR 2a and 2b appear absent in normal tissue and present in benign and malignant thyroid tissue (P < 0.02). This suggests that focussed SSTR2 treatment may be a potential therapeutic target.

AB - Somatostatin analogues are commercially available and used for the management of acromegaly and neuroendocrine tumours, but the expression of the receptors as a target in thyroid disease has not been explored. To assess somatostatin (SST) and somatostatin receptor (SSTR1-5) expression in both normal and thyroid disorders, as a potential target for somatostatin analogue therapy, 67 thyroid tissue specimens were reviewed: 12 differentiated thyroid carcinomas, 14 follicular adenomas, 17 multinodular goitres, 14 Graves disease, 10 Hashimotos thyroiditis specimens and five normal thyroids. Tissue was immunostained for SST and SSTR1-5. Positivity and the degree of positivity were recorded by double-blinded observers. Somatostatin receptor expression was highly expressed in normal tissue for SSTR1, 3, 4 and 5 (5 of 5, 4 of 5, 4 of 5 and 5 of 5 respectively) whilst SST and SSTR 2a and b were not expressed at all. The commonest receptor expressed for all pathological subtypes grouped together was SSTR2b (63 specimens). The commonest receptors expressed in differentiated thyroid cancer were SSTR5 (11 of 12 specimens) and SSTR2b (10 of 12 specimens). The commonest receptor expressed in benign disease was SSTR2b (53 of 55 specimens). SSTR5 was significantly under-expressed in Graves disease (P < 0.05). This study illustrates that SSTR 1, 3, 4 and 5 are highly expressed in normal, benign and malignant thyroid tissue. SSTR 2a and 2b appear absent in normal tissue and present in benign and malignant thyroid tissue (P < 0.02). This suggests that focussed SSTR2 treatment may be a potential therapeutic target.

KW - Analogue

KW - Octreotide

KW - Receptor

KW - Somatostatin

KW - Thyroid

UR - http://www.scopus.com/inward/record.url?scp=84877912890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877912890&partnerID=8YFLogxK

U2 - 10.1111/iep.12024

DO - 10.1111/iep.12024

M3 - Article

VL - 94

SP - 226

EP - 229

JO - International Journal of Experimental Pathology

JF - International Journal of Experimental Pathology

SN - 0959-9673

IS - 3

ER -